Nexletol is the first non-statin, LDL-cholesterol lowering drug approved by the FDA in nearly 20 years. Credit: The U.S. Food and Drug Administration.

The US Food and Drug Administration (FDA) has approved Esperion’s LDL-cholesterol (LDL-C) lowering drug Nexletol to treat heterozygous familial hypercholesterolemia (HeFH) in adults.

Also, the drug is indicated for the treatment of atherosclerotic cardiovascular disease (ASCVD) patients requiring further LDL-C lowering.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Meant for adjunct use with diet and maximally tolerated statin therapy, Nexletol is the first non-statin medicine approved by the FDA in nearly 20 years.

The drug, which comprises bempedoic acid and ezetimibe combination, is designed as an inhibitor of ATP Citrate Lyase (ACL). It lowers LDL-C by blocking cholesterol synthesis in the liver.

Esperion president and CEO Tim Mayleben said: “Even with maximally tolerated statins, which may mean no statin at all, some of these patients can’t achieve their LDL-C goals. Today’s approval provides them with a new medicine to go along with a healthy diet.”

FDA approval comes from the results of the global Phase III LDL-C lowering programme performed in more than 3,000 patients. The drug, given with moderate or high-intensity statins, led to an average of 18% placebo corrected decrease in LDL-C.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Nexletol is expected to be priced at approximately $10 per fill, up to a three-month supply, available in the US through a prescription from 30 March.

The FDA also approved Eli Lilly’s Trulicity (dulaglutide) to mitigate major adverse cardiovascular events (MACE) in adult type 2 diabetes patients with established cardiovascular disease or cardiovascular risk factors.

Furthermore, Lundbeck secured the FDA nod for Vyepti (eptinezumab-jjmr) as a preventive therapy of migraine in adults. The medication is said to be the first intravenous migraine prevention treatment approved for use in the US.